Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Tuesday, August 23, 2011
Dual Hepatitis B, C Infection Ups Lifetime HCC Risk
Yen-Tsung Huang, from Harvard University in Boston, and colleagues investigated the lifetime risk and gender difference of HCC in patients with chronic HBV and/or HCV. From 1991 to 1992, 477 cases of HCC were identified from 23,820 Taiwan residents (aged 30 to 75 years) through computerized data linkage with national cancer registry and death certification systems. Seromarkers and viral load of HBV and HCV were estimated in samples collected at enrollment.